The ARL14EP Knockout HT29 Polyclonal Cells product comprises a polyclonal population of HT-29 human colorectal adenocarcinoma epithelial cells in which the ARL14EP gene has been disrupted using CRISPR/Cas9 genome editing. This knockout model is delivered as a mixed pool of edited cells, providing a loss-of-function system for investigating ARL14EP-dependent cellular processes without the selection of a single clonal isolate. The polyclonal format captures a spectrum of genetic disruptions across the cell population, enabling robust and reproducible functional studies in a genetically heterogeneous background that more closely mimics native tumor cell diversity.
The parental HT-29 cell line is a well-characterized epithelial model originally derived from a primary colorectal adenocarcinoma. These cells display adherent, epithelial morphology and are widely employed in intestinal cell biology and colorectal cancer research due to their ability to recapitulate aspects of tumorigenesis, differentiation, and drug response in vitro. HT-29 cells are particularly valued for studying signaling pathways that drive colon cancer progression and metastasis, as well as for screening therapeutic candidates. The use of this cell background ensures that the functional consequences of ARL14EP knockout can be examined in a clinically relevant colorectal adenocarcinoma context.
ARL14EP is a dedicated effector of the ADP-ribosylation factor-like 14 (ARL14) small GTPase, essential for recruiting myosin VI to Golgi membranes. This molecular interaction governs Golgi-to-endosome vesicle trafficking and drives actin cytoskeleton reorganization. ARL14EP operates downstream of ARL14 and upstream of myosin VI and actin filaments, forming an axis that integrates membrane dynamics with migratory function. Disruption of ARL14EP compromises Golgi organization, impairs vesicle budding, and reduces actin-dependent cell motility. These pathway components??ARL14, ARL14EP, myosin VI, and actin??are central to directional cell movement and are frequently dysregulated in metastatic carcinoma.
In HT-29 colorectal adenocarcinoma cells, the ARL14?CARL14EP?Cmyosin VI axis sustains Golgi organization and polarized secretion, which are frequently dysregulated in metastatic cancer. This polyclonal knockout model enables precise dissection of how ARL14EP loss disrupts intracellular trafficking, actin dynamics, and cell motility, offering a physiologically relevant system to study the molecular drivers of colorectal carcinoma invasion and metastasis.
This knockout product is directly applicable to diverse experimental workflows. Researchers can confirm protein depletion by western blotting, assess Golgi morphology via immunofluorescence, and quantify migratory and invasive capacity using scratch wound healing and transwell assays. RT-qPCR enables gene expression profiling downstream of ARL14EP. Moreover, the polyclonal format supports functional genomic screening to identify synthetic lethal partners or compensatory pathways in colon adenocarcinoma. For additional information and technical assistance, please contact Ascent Research.
